Daragh Heitzman, MD
Neurology · Dallas, TXNPI 1023083961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Amylyx Pharmaceuticals, Inc. at 37.8% of the total. Reporting peaked in 2023 at $12,376 and has fallen 87.0% since, to $1,611 in 2025.
Across 763 payments — averaging $35.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amylyx Pharmaceuticals, Inc.$10K
- Tanabe Pharma America, Inc.$4K
- AbbVie$1K
- Genentech USA, Inc.$930
- UCB, Inc.$814
- Biogen$711
- plus $9K from 52 others
Across 39 payments — averaging $7183.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mitsubishi Tanabe Pharma Development America, Inc.$125K
- Biohaven Pharmaceutical Holding Company Ltd.$42K
- Orion Corporation$42K
- UCB SA$36K
- Mallinckrodt Enterprises LLC$13K
- Amylyx Pharmaceuticals, Inc.$13K
- plus $9K from 2 others
Across 7 payments — averaging $66,889 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$468K
What the payments were for
- Consulting fees$3,57513%
- Speaking & faculty fees$8,60831%
- Travel & lodging$9023%
- Food & beverage$14,23352%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELYVRIO$9,770
- Radicava$3,575
- Rystiggo$209
- NEXVIAZYME$122
- Leqembi$120
How this compares
$27,328 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 38 | $531,896 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 40 | $493,740 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 44 | $457,796 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $226,640 |
| TysabriNatalizumab | 11 | $105,042 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $74,125 |
| Riluzole | 109 | $27,492 |
| NeuproRotigotine | 18 | $16,710 |
| Pyridostigmine Bromide | 60 | $7,572 |
| Glycopyrrolate | 67 | $4,542 |
| Memantine Hcl | 118 | $4,129 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 144 | $3,785 |
| Gabapentin | 195 | $3,721 |
| Baclofen | 44 | $2,188 |
| Donepezil Hcl | 132 | $2,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amylyx Pharmaceuticals, Inc.Relyvrio | $10,337 | $493,74040 claims |
| Grifols USA, LLCGamunex-C | $80 | $457,79644 claims |
| CSL BehringPrivigen | $134 | $226,64017 claims |
| BiogenTysabri | $711 | $105,04211 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $282 | $74,12539 claims |
| UCB, Inc.Neupro | $814 | $16,71018 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $130 | $7,57260 claims |
| Upsher-smith Laboratories LLCTopiramate | $68 | $15215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.